与SNRIs相关的胃肠道不良事件:基于FAERS的药监测研究
Journal of affective disorders
|May 29, 2025
概括
氨酸 - 氨酸反吸收抑制剂 (SNRIs) 可以导致胃肠道不良事件 (AE). 这项研究发现便秘,口腔干燥,恶心和吐是显著的风险,特别是在老年人中.
科学领域:
- 药物监督 药物监督 药物监督
- 临床药理学 临床药理学
- 胃肠病学 胃肠病学
背景情况:
- 重度抑郁症是常见的,以氨酸 - 上腺素再吸收抑制剂 (SNRIs) 作为主要治疗方法.
- 与SNRIs相关的胃肠道不良事件 (AEs) 尚未得到充分研究,尽管它们影响了治疗的坚持和疗效.
研究的目的:
- 系统地评估与SNRIs相关的胃肠道不良事件.
- 为了确定特定的胃肠道副作用和患有更高风险的患者人口统计数据.
主要方法:
- 对2004-2024年FDA不良事件报告系统 (FAERS) 数据的回顾性分析.
- 涉及的114,148份报告涉及五种SNRI药物:文拉法辛,德斯文拉法辛,米尔纳西普兰,莱沃米利纳西普兰和杜洛西丁.
主要成果:
- 胃肠道AE是所有研究的SNRIs的前十个器官系统类别之一.
- 确定了18个积极的药监信号,具有便秘,口腔干燥,口腔低听觉,恶心和吐的显著风险.
- 中年和老年患者对与SNRI相关的胃肠道AE具有更高的敏感性.
结论:
- SNRIs 具有显著的胃肠道风险,需要仔细选择和监测药物.
- 进一步研究这些AE的机制和长期影响至关重要.
相关概念视频
Pharmacovigilance
789
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
789
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
225
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
225
Assessment of the Gastrointestinal System I: Subjective Data
160
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
160
Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
335
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
335
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153


